PALI

Palisade Bio, Inc. NASDAQ Listed Mar 30, 2007

Healthcare ·Biotechnology ·US · palisadebio.com

$1.99

After hrs $1.94 +0.00%

Mkt Cap $333.2M

52w Low $0.53 62.7% of range 52w High $2.86

50d MA $1.98 200d MA $1.63

P/E (TTM) -6.6x

EV/EBITDA 0.1x

P/B 0.9x

Debt/Equity 0.0x

ROE -13.0%

P/FCF -12.1x

RSI (14) —

ATR (14) —

Beta 1.47

50d MA $1.98

200d MA $1.63

Avg Volume 4.1M

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

SIC Code

2836

CIK (SEC)

1357459

Phone

858 704 4900

5800 Armada Drive · Carlsbad, CA 92008 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 23, 2026	AMC	-0.02	-0.04	-100.0%	1.91	-0.5%	+4.7%	+0.0%	-2.0%	+2.0%	-11.0%	—
Nov 10, 2025	AMC	-0.32	-0.38	-18.8%	1.77	-0.6%	+2.8%	+12.1%	-8.3%	+14.4%	-3.3%	—
Aug 11, 2025	AMC	-0.48	-0.58	-20.8%	0.74	-7.8%	+1.4%	+8.1%	+0.5%	-1.7%	+0.0%	—
May 12, 2025	AMC	-0.84	-0.47	+44.0%	0.77	+4.0%	-5.1%	-4.3%	-2.6%	+1.0%	+0.2%	—
Mar 24, 2025	AMC	-1.99	-0.69	+65.3%	0.70	+2.6%	-1.6%	+0.7%	-0.8%	-0.1%	-1.1%	—
Nov 12, 2024	AMC	-3.35	-2.32	+30.7%	2.38	+3.4%	-7.6%	+19.1%	-3.8%	-5.2%	+1.7%	—
Aug 12, 2024	AMC	-2.93	-3.32	-13.3%	3.66	-0.3%	+1.1%	-3.2%	+3.6%	+6.2%	-8.4%	—
May 13, 2024	AMC	-4.80	-4.59	+4.4%	6.22	-3.5%	+0.3%	+2.2%	+1.3%	-1.5%	-8.0%	—
Mar 26, 2024	AMC	-5.17	-3.75	+27.5%	5.59	+2.0%	+6.1%	+1.0%	-2.3%	-1.9%	+1.7%	—
Nov 9, 2023	AMC	-0.39	-7.35	-1784.6%	7.80	+2.9%	+1.9%	-0.6%	-1.3%	+1.9%	-1.3%	—
Aug 11, 2023	AMC	-0.45	-7.95	-1666.7%	10.65	-5.4%	-7.0%	-6.1%	-6.7%	+7.1%	-1.6%	—
May 12, 2023	AMC	-0.72	-8.10	-1025.0%	23.85	+2.5%	+0.0%	+0.6%	+0.6%	-2.5%	-5.1%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 13	Brookline Capital	Maintains	Buy → Buy	—	$0.77	$0.80	+4.0%	-5.1%	-4.3%	-2.6%	+1.0%	+0.2%
Nov 13	Maxim Group	Maintains	Buy → Buy	—	$2.38	$2.46	+3.4%	-7.6%	+19.1%	-3.8%	-5.2%	+1.7%
May 1	Maxim Group	Maintains	Buy → Buy	—	$6.03	$7.95	+31.8%	+17.4%	+3.0%	+6.2%	+9.3%	-6.6%
Apr 16	Maxim Group	Maintains	Buy → Buy	—	$4.16	$8.75	+110.3%	+42.5%	+11.3%	-23.2%	-7.1%	+4.7%
Nov 17	Maxim Group	Upgrade	Hold → Buy	—	$7.85	$8.25	+5.1%	+15.5%	-0.8%	-1.7%	-1.8%	+1.0%
May 16	Ladenburg Thalmann	Maintains	Buy → Buy	—	$23.85	$23.70	-0.6%	+0.6%	+0.6%	-2.5%	-5.1%	-1.3%
Mar 30	Maxim Group	Upgrade	Hold → Buy	—	$25.20	$29.40	+16.7%	+57.7%	+32.8%	-35.8%	-10.2%	+7.4%
Aug 19	Maxim Group	Downgrade	Buy → Hold	—	$123.08	$126.75	+3.0%	+9.7%	-10.4%	+4.0%	+4.4%	+7.3%
Feb 2	Ladenburg Thalmann	Maintains	Buy → Buy	—	$922.50	$960.00	+4.1%	-17.1%	-17.5%	+9.9%	+3.7%	+8.3%
Aug 31	Maxim Group	Maintains	Buy → Buy	—	$2047.50	$2317.50	+13.2%	+2.9%	-5.0%	+3.4%	-1.1%	+5.9%

Data updated apr 26, 2026 6:33pm · Source: massive.com